<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02021006</url>
  </required_header>
  <id_info>
    <org_study_id>PREDICT trial</org_study_id>
    <nct_id>NCT02021006</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministero della Salute, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IL Sogno di Stefano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The exact role of urinary tract infection in the appearance of chronic kidney disease is&#xD;
      unclear. Children with congenital malformations of kidney and urinary tract have the higher&#xD;
      risk of impairment of renal function. To understand if the use of antibiotic prophylaxis can&#xD;
      reduce the risk of urinary tract infection in children with these malformations, this study&#xD;
      will randomize children in two groups. Group A will not take antibiotic prophylaxis, Group B&#xD;
      will take antibiotic prophylaxis for 2 years. This study will assess if antibiotic&#xD;
      prophylaxis reduce the risk of urinary tract infections in these children and if urinary&#xD;
      tract infections influence the appearance of renal damage.&#xD;
&#xD;
      Our hypothesis is that prophylaxis reduce the risk of infection in severe vesicoureteral&#xD;
      reflux and that urinary tract infections, in morphologically normal kidneys, will not result&#xD;
      in chronic renal failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial urinary tract infections (UTI) are common in young children. The presence of fever&#xD;
      is considered to be a marker of renal parenchymal involvement. Renal damage during the acute&#xD;
      phase of infection may lead to scarring, yet the role that scarring plays in the appearance&#xD;
      of chronic kidney failure is unknown. It is also unclear what influence scars have on the&#xD;
      natural course of kidney function, especially in children with renal hypodysplasia, with or&#xD;
      without vesicoureteral reflux (VUR). Renal hypodysplasia is the most common cause for&#xD;
      dialysis and transplantation in the pediatric population.&#xD;
&#xD;
      Patients suffering from recurrent UTIs and VUR have often undergone corrective surgery. For&#xD;
      many years, it was also thought necessary to prescribe long-term antibiotic prophylaxis to&#xD;
      all children with VUR. These treatment strategies were based on the ideas and opinions of the&#xD;
      experts, rather than on hard scientific evidence. As regards the prevention of recurrent UTIs&#xD;
      and the subsequent development of renal scarring, a long-term international study on Reflux&#xD;
      was not able to demonstrate that surgical correction is more effective than antibiotic&#xD;
      prophylaxis. Very little data is available regarding the use of long-term antibiotic&#xD;
      prophylaxis in children with high grade reflux with or without renal hypodysplasia.&#xD;
&#xD;
      The use of antibiotics during the first few months of life has been associated with a&#xD;
      significant increase in body mass index (BMI). Even though this effect is probably limited,&#xD;
      it could have a significant impact on public health given the widespread use of antibiotics&#xD;
      and due to the considerable increase in cases of pediatric and adult obesity seen over the&#xD;
      last few years.&#xD;
&#xD;
      In spite of the lack of evidence, the use of prophylaxis is largely routine practice in most&#xD;
      centres. Therefore, a randomized study is necessary in order to evaluate whether prophylaxis&#xD;
      reduces the risk of symptomatic infections and subsequent renal damage.&#xD;
&#xD;
      To assess the role of prophylaxis in patient with high grade vesicoureteral reflux we will&#xD;
      perform a multicentre, prospective, randomized, controlled, open-label, study.&#xD;
&#xD;
      Patients enrolled will be randomized in two groups:&#xD;
&#xD;
      Group A: no antibiotic prophylaxis. Group B: antibiotic prophylaxis for 24 months. The choice&#xD;
      of which antibiotic to prescribe from the list below is left to the discretion of each&#xD;
      investigator, on the basis of local antibiotic resistance patterns.&#xD;
&#xD;
        -  nitrofurantoin 1.5-2 mg/kg per day&#xD;
&#xD;
        -  amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to&#xD;
           amoxicillin)&#xD;
&#xD;
        -  cefixime 2 mg/kg per day&#xD;
&#xD;
        -  trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to&#xD;
           trimethoprim)&#xD;
&#xD;
      The study is comprised of:&#xD;
&#xD;
        -  Phase 1: Pre-randomization - screening tests to determine eligibility for the trial.&#xD;
&#xD;
        -  Phase 2: Active treatment - this phase follows randomization and foresees 24 months of&#xD;
           antibiotic prophylaxis for Group B and clinical surveillance for Group A.&#xD;
&#xD;
        -  Phase 3: Follow-up - a further 36 months of clinical, laboratory and instrumental&#xD;
           evaluation of renal function and the progression of renal damage for a total follow-up&#xD;
           period of 5 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urinary tract infections rate</measure>
    <time_frame>during the first 24 months from enrolment</time_frame>
    <description>Urinary tract infections will be strictly monitored in all enrolled patients (both group A and group B). The rate of urinary tract infections in the first 24 months from the enrolment will be compared between 2 groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>febrile urinary tract infections</measure>
    <time_frame>during the first 24 months from enrolment</time_frame>
    <description>Febrile urinary tract infections will be strictly monitored in all enrolled patients (both group A and group B). The rate of febrile urinary tract infections in the first 24 months from the enrolment will be compared between 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal scars</measure>
    <time_frame>at 2 years and 5 years from enrolment</time_frame>
    <description>the appearance of renal scars in a dimercaptosuccinic acid (DMSA) scan will be detected at 2 and 5 years from enrolment and compared between the 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine (renal function)</measure>
    <time_frame>at the enrolment,1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>The renal function (serum creatinine) will be monitored for all enrolled patients to explore the appearance and progression of renal damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypertension</measure>
    <time_frame>at 4, 8, 12, 18, 24, 36, 48, 60 months from enrolment</time_frame>
    <description>the appearance of hypertension will be monitored at every visit in all enrolled children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proteinuria</measure>
    <time_frame>at 4, 8, 12, 18, 24, 36, 48, 60 months from enrolment</time_frame>
    <description>the appearance of proteinuria will be monitored at every visit in all enrolled children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>at 2 and 5 years from enrolment</time_frame>
    <description>body mass index will be evaluated at 2 and 5 years of follow-up and it will be correlated to the use of antibiotic prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum cystatin C (renal function)</measure>
    <time_frame>at the enrolment,1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>The renal function (serum cystatin-C) will be monitored for all enrolled patients to explore the appearance and progression of renal damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modification in gut microbiota induced by continuous antibiotic exposure during the first months of life</measure>
    <time_frame>at the enrollment, 4 months, 8 months, 12 months, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>A stool sample will be collected, frozen and stored for gut microbiota and resistome profile analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Vesicoureteral Reflux</condition>
  <condition>Renal Hypodysplasia, Nonsyndromic, 1</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>ANTIBIOTIC PROPHYLAXIS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children in this arm will take antibiotic prophylaxis for 2 years. Patients in this arm will do clinical/instrumental follow-up for 5 years.&#xD;
The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs&#xD;
Physicians can chose one the following schedules:&#xD;
nitrofurantoin 1.5-2 mg/kg per day&#xD;
Amoxicillin-Potassium Clavulanate Combination 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)&#xD;
cefixime 2 mg/kg per day&#xD;
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO PROPHYLAXIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children in this arm will not take antibiotic prophylaxis. Patients in this arm will do clinical/instrumental follow-up for 5 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitrofurantoin</intervention_name>
    <description>antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs&#xD;
Physicians can chose one the following schedules:&#xD;
nitrofurantoin 1.5-2 mg/kg per day&#xD;
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)&#xD;
cefixime 2 mg/kg per day&#xD;
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)</description>
    <arm_group_label>ANTIBIOTIC PROPHYLAXIS</arm_group_label>
    <other_name>Furadantin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No prophylaxis</intervention_name>
    <description>children will be followed, but no antibiotic prophylaxis will be administered</description>
    <arm_group_label>NO PROPHYLAXIS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-Potassium Clavulanate Combination</intervention_name>
    <description>antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs&#xD;
Physicians can chose one the following schedules:&#xD;
nitrofurantoin 1.5-2 mg/kg per day&#xD;
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)&#xD;
cefixime 2 mg/kg per day&#xD;
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)</description>
    <arm_group_label>ANTIBIOTIC PROPHYLAXIS</arm_group_label>
    <other_name>amoxicilline/clavulanic acid, augmentin, clavulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim/sulfamethoxazole</intervention_name>
    <description>antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs&#xD;
Physicians can chose one the following schedules:&#xD;
nitrofurantoin 1.5-2 mg/kg per day&#xD;
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)&#xD;
cefixime 2 mg/kg per day&#xD;
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)</description>
    <arm_group_label>ANTIBIOTIC PROPHYLAXIS</arm_group_label>
    <other_name>bactrim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefixime</intervention_name>
    <description>antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs&#xD;
Physicians can chose one the following schedules:&#xD;
nitrofurantoin 1.5-2 mg/kg per day&#xD;
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)&#xD;
cefixime 2 mg/kg per day&#xD;
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)</description>
    <arm_group_label>ANTIBIOTIC PROPHYLAXIS</arm_group_label>
    <other_name>cefixoral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 1 and 4 months (&gt; 4 weeks and &lt;20 weeks of post-natal age)&#xD;
&#xD;
          -  Gestational age &gt; 35 weeks&#xD;
&#xD;
          -  Glomerular filtration rate (calculated according to Schwartz) &gt; 15 ml/min/1.73 m2&#xD;
&#xD;
          -  No previous symptomatic UTI&#xD;
&#xD;
          -  Imaging Diagnostic work-up completed and presence of grade III to V vesicoureteral&#xD;
             reflux&#xD;
&#xD;
          -  Informed consent of parents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;1 and &gt;4 months&#xD;
&#xD;
          -  Gestational age &lt; 35 weeks&#xD;
&#xD;
          -  Glomerular filtration rate (calculated according to Schwartz) &lt; 15 ml/min/1.73 m2 at&#xD;
             three months of age&#xD;
&#xD;
          -  Patients with neurogenic bladder, myelomeningocele, ureteropelvic junction and/or&#xD;
             ureterovesical junction obstruction, or other malformations leading to potential&#xD;
             voiding disturbances.&#xD;
&#xD;
          -  Presence of urethral valves&#xD;
&#xD;
          -  Patients with no or low grade reflux (grade I and II).&#xD;
&#xD;
          -  Hypersensitivity to the all the utilized antimicrobial agent&#xD;
&#xD;
          -  Children with serious clinical conditions which, according to the investigator,&#xD;
             prevent them from being included in the study cohort.&#xD;
&#xD;
          -  Use of experimental drugs in the month previous to the beginning of the study&#xD;
&#xD;
          -  Children unable to follow the established protocol procedures or whose parents are&#xD;
             unable to sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Montini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franz Schaefer, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Center for Pediatrics and Adolescent Medicine Division of Pediatric Nephrology, Heidelberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Otto Mehls, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Pediatrics and Adolescent Medicine Division of Pediatric Nephrology, Heidelberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lutz T. Weber, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ärztlicher Leiter der Kindernephrologie Klinik und Poliklinik für Kinder- und Jugendmedizin Uniklinik Köln - Köln</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aleksandra M Zurowska, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Gdansk, Department Paediatric &amp; Adolescent Nephrology &amp; Hypertension - Gdansk - Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatos Yalcinkaya, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatric Nephrology, School of Medicine, Ankara University, Ankara, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esra Baskin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paediatric Nephrology Division, Department of Paediatrics, Faculty of Medicine, Baskent University, Ankara, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrico Verrina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UOC Nefrologia, Dialisi e Trapianto, IRCCS Giannina Gaslini, Genova, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Morello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Czarniak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk - Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Nephrology Dialysis and Transplant Unit IRCCS Ca'Granda</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 1, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</investigator_affiliation>
    <investigator_full_name>Giovanni Montini</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>antibiotic prophylaxis</keyword>
  <keyword>vesicoureteral reflux</keyword>
  <keyword>congenital abnormalities of kidney</keyword>
  <keyword>renal hypodysplasia</keyword>
  <keyword>chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Vesico-Ureteral Reflux</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Nitrofurantoin</mesh_term>
    <mesh_term>Cefixime</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

